Peptide Supply Chain Educational Guide
An unvarnished reference covering compounding pharmacy distinctions (503A vs 503B), regulatory compliance frameworks, USP <797>/<795> cleanroom standards, and 3rd-party batch quality testing.
Compounding Pharmacies: 503A vs 503B
Patient-Specific Prescription Dispensing
503A facilities compound medications pursuant to individual patient-specific prescriptions. Regulated primarily by State Boards of Pharmacy, 503A compounders adhere to USP <797> (sterile preparation) and USP <795> (non-sterile preparation) standards.
- Requires individual patient prescription
- State Board of Pharmacy oversight
- USP <797> sterile cleanroom requirements
Bulk Office-Stock & Batch Production
503B outsourcing facilities are permitted to compound batch supplies without individual patient-specific prescriptions for hospital or clinic office stock. They are held to cGMP (current Good Manufacturing Practice) standards under direct FDA inspection.
- Office-stock bulk distribution allowed
- Federal FDA inspection & cGMP compliance
- Mandatory 6-month product reporting to FDA
Ready to explore verified supply chain data?
Get instant access to audited compounding pharmacy records, cGMP API suppliers, and custom order routing tools.